Memantin Stada (Memantine Hydrochloride)

Memantine hydrochloride blocks the NMDA‑type glutamate receptor in a non‑competitive manner, limiting excessive calcium entry into neurons. This reduces excitotoxic damage that contributes to neurodegeneration, thereby supporting neuronal function in Alzheimer’s disease.

The specific dose of Memantin Stada is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Dosage adjustments are made according to individual therapeutic needs and safety considerations.

Safety data for memantine hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantin Stada belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While acetylcholinesterase inhibitors enhance cholinergic transmission, memantine reduces glutamate‑mediated excitotoxicity, offering an alternative mechanism that can be used alone or in combination with other agents.

Memantin Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Memantin Stada is taken orally, usually as a tablet. The tablet should be swallowed whole with water and can be taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious risks, though uncommon, include seizures, severe allergic reactions such as rash or angioedema, Stevens‑Johnson syndrome, hepatic injury, cardiac arrhythmias, and psychotic episodes. Patients should be monitored for any of these events and seek immediate medical attention if they occur.

Memantin Stada is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists.